Video

Dr Clifford Goodman Outlines the Pros and Cons of NCCN Guidelines

Over the years, the National Comprehensive Cancer Network Guidelines have become the market leader for clinical guidelines to consult, but with that success comes responsibility and scrutiny, according to Clifford Goodman, PhD.

Over the years, the National Comprehensive Cancer Network (NCCN) Guidelines have become the market leader for clinical guidelines to consult, but with that success comes responsibility and scrutiny, according to Clifford Goodman, PhD, senior vice president and director at the Center for Comparative Effectiveness Research at The Lewin Group.

NCCN has been successful because it can quickly update its Guidelines and it is easy to access. However, the biggest drawback does not have to do with the content, but how the guidelines are being used.

“Most patients consider they have insufficient information upon which to base decisions at the time they’ve got to make those decisions,” Dr Goodman said.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Andrew Kuykendall, MD, Moffitt Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Dr Brian Slomovitz
Coral Omene, MD, PhD, sitting for a vieo interview
Dr Ola Landgren
David Awad, PharmD, BCOP
Screenshot of Coral Omene, MD, PhD
Dr Brian Slomovitz
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo